CY1107758T1 - Πολυμορφα ενος αναλογου εποθεινολης - Google Patents

Πολυμορφα ενος αναλογου εποθεινολης

Info

Publication number
CY1107758T1
CY1107758T1 CY20071101304T CY071101304T CY1107758T1 CY 1107758 T1 CY1107758 T1 CY 1107758T1 CY 20071101304 T CY20071101304 T CY 20071101304T CY 071101304 T CY071101304 T CY 071101304T CY 1107758 T1 CY1107758 T1 CY 1107758T1
Authority
CY
Cyprus
Prior art keywords
polymorphone
ethinological
analog
methods
polymorphs
Prior art date
Application number
CY20071101304T
Other languages
English (en)
Inventor
John D Dimarco
Jack Z Gougoutas
Imre M Vitez
Martha Davidovich
Michael Galella
Timothy M Malloy
Zhenrong Guo
Denis Favreau
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22845469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107758(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1107758T1 publication Critical patent/CY1107758T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Παρέχονται σύμφωνα με την παρούσα εφεύρεση δύο κρυσταλλικά πολύμορφα, ορισθέντα Μορφή Α και Μορφή Β, αντίστοιχα, καθώς και μίγματα αυτών, από ένα ανάλογο εποθειλόνης που αντιπροσωπεύεται από τον τύπο (I). Επίσης παρέχονται μέθοδοι για τον σχηματισμό των νέων πολύμορφων, θεραπευτικές μέθοδοι για την χρήση αυτών και φαρμακευτικές μορφές δοσολογίας που τα περιέχουν.
CY20071101304T 2000-08-16 2007-10-11 Πολυμορφα ενος αναλογου εποθεινολης CY1107758T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22559000P 2000-08-16 2000-08-16
EP01959536A EP1309597B1 (en) 2000-08-16 2001-08-01 Polymorphs of an epothilone analog

Publications (1)

Publication Number Publication Date
CY1107758T1 true CY1107758T1 (el) 2013-06-19

Family

ID=22845469

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101304T CY1107758T1 (el) 2000-08-16 2007-10-11 Πολυμορφα ενος αναλογου εποθεινολης

Country Status (42)

Country Link
US (4) US6689802B2 (el)
EP (1) EP1309597B1 (el)
JP (1) JP5046467B2 (el)
KR (1) KR100810342B1 (el)
CN (1) CN1269821C (el)
AR (1) AR034259A1 (el)
AT (1) ATE366735T1 (el)
AU (2) AU2001281082B2 (el)
BG (1) BG66132B1 (el)
BR (1) BR0113234A (el)
CA (1) CA2418109C (el)
CY (1) CY1107758T1 (el)
CZ (1) CZ305523B6 (el)
DE (1) DE60129334T2 (el)
DK (1) DK1309597T3 (el)
EE (1) EE05273B1 (el)
ES (1) ES2288518T3 (el)
GE (1) GEP20053495B (el)
HK (1) HK1052010A1 (el)
HR (1) HRP20030190B1 (el)
HU (1) HU229314B1 (el)
IL (2) IL153993A0 (el)
IS (1) IS2845B (el)
LT (1) LT5138B (el)
LV (1) LV13032B (el)
MX (1) MXPA03001431A (el)
MY (1) MY134129A (el)
NO (1) NO328500B1 (el)
NZ (1) NZ523722A (el)
PE (1) PE20020290A1 (el)
PL (1) PL205628B1 (el)
PT (1) PT1309597E (el)
RO (1) RO123296B1 (el)
RU (1) RU2272039C2 (el)
SI (1) SI21100B (el)
SK (1) SK287876B6 (el)
TW (1) TWI320040B (el)
UA (1) UA75365C2 (el)
UY (1) UY26886A1 (el)
WO (1) WO2002014323A2 (el)
YU (1) YU12103A (el)
ZA (1) ZA200300522B (el)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242469B1 (en) * 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
EP1353667A1 (en) * 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
IL156578A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog
PL363362A1 (en) 2001-02-20 2004-11-15 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
JP2004529904A (ja) * 2001-03-14 2004-09-30 ブリストル−マイヤーズ　スクイブ　カンパニー 増殖性疾患の治療のためのエポシロン類似体および化学療法剤の組み合わせ
JP2005522461A (ja) * 2002-03-08 2005-07-28 ノバルティス　アクチエンゲゼルシャフト エポチロン誘導体およびアルキル化剤を含む組合せ剤
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
NZ538522A (en) * 2002-08-23 2008-03-28 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
PL1817013T3 (pl) 2004-11-18 2009-01-30 Bristol Myers Squibb Co Dojelitowa powlekana peletka zawierająca Ixabepilone
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
WO2007086879A2 (en) 2005-02-11 2007-08-02 University Of Southern California Method of expressing proteins with disulfide bridges
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
US7693596B2 (en) 2005-12-14 2010-04-06 Dell Products L.P. System and method for configuring information handling system integrated circuits
US20080286325A1 (en) * 2006-01-05 2008-11-20 Med Institute, Inc. Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
US7919108B2 (en) * 2006-03-10 2011-04-05 Cook Incorporated Taxane coatings for implantable medical devices
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20110104664A1 (en) 2006-03-31 2011-05-05 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to micortubule-stabilizing agents
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
MX2009001635A (es) 2006-08-16 2009-02-23 Novartis Ag Forma de cristal de epotilona b y su uso en composiciones farmaceuticas.
US8463852B2 (en) * 2006-10-06 2013-06-11 Oracle International Corporation Groupware portlets for integrating a portal with groupware systems
US20110124690A1 (en) * 2007-02-23 2011-05-26 Danishefsky Samuel J Compositions and methods for treating cancer or a neurotrophic disorder
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
ES2625637T3 (es) 2010-02-12 2017-07-20 Pharmascience Inc. Compuestos de unión al dominio BIR IAP
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
KR20130086534A (ko) * 2010-06-01 2013-08-02 플러스 케미칼스, 에스.에이. 익사베필론의 고체 형태
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
CN103183681B (zh) * 2013-03-06 2016-01-13 浙江海正药业股份有限公司 伊沙匹隆的新晶型及其制备方法
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
CN105517577A (zh) 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
WO2021152107A1 (en) 2020-01-31 2021-08-05 Oncology Venture ApS Methods for predicting ixabepilone responsiveness in cancer patients
CN112457320A (zh) * 2020-11-30 2021-03-09 湖北宏中药业股份有限公司 一种提高伊沙匹隆合成反应速率的方法
CN112409366A (zh) * 2020-11-30 2021-02-26 湖北宏中药业股份有限公司 一种伊沙匹隆二聚体的高收率制备方法
CN112375085A (zh) * 2020-11-30 2021-02-19 湖北宏中药业股份有限公司 一种伊沙匹隆反应液的高收率高纯度处理方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1000809A (en) * 1960-11-02 1965-08-11 James Oakes & Company Riddings Pipe manufacture
DE2308418B2 (de) * 1972-06-21 1976-04-08 Petzetakis, Aristovoulos George, Moschaton, Piräus (Griechenland) Verfahren und vorrichtung zum herstellen eines insbesondere grosskalibrigen rohres aus thermoplastischem kunststoff
JPS5240337B2 (el) * 1973-01-29 1977-10-12
SE386365B (sv) * 1973-07-25 1976-08-09 L Brendling Behallare av plast, gummi eller annat bojligt material, spec. avsedd for uppsamling av urin och/eller fekalier
JPS6398413A (ja) * 1986-10-15 1988-04-28 Smc Corp 二重管およびその連続製造法
DE3927569A1 (de) * 1989-08-21 1991-02-28 Fritz Egger Gmbh Elektroabscheider zum abscheiden von schwebstoffen aus gasen
DE3939714A1 (de) * 1989-12-01 1991-06-06 Baedje K H Meteor Gummiwerke Schlauch
WO1991011012A1 (en) * 1990-01-05 1991-07-25 Orscheln Co. Flexible synthetic plastic conduit
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE4206096A1 (de) * 1992-02-27 1993-09-02 Wolf Woco & Co Franz J Koaxialrohr
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
ATE261961T1 (de) 1995-11-17 2004-04-15 Biotechnolog Forschung Gmbh Epothilon-derivate, ihre herstellung und verwendung
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
EP0923583A1 (de) 1996-08-30 1999-06-23 Novartis AG Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE59712968D1 (de) 1996-11-18 2008-10-30 Biotechnolog Forschung Gmbh Epothilone E und F
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
WO1998038192A1 (de) 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Seitenkettenmodifizierte epothilone
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ATE224882T1 (de) 1997-07-16 2002-10-15 Schering Ag Thiazolderivate, verfahren zur herstellung und verwendung
AU9340998A (en) 1997-08-09 1999-03-01 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
DE19747580A1 (de) 1997-10-28 1999-04-29 Siemens Ag Rangierfeld mit Anschlußleiste
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
AU753519B2 (en) 1998-02-05 2002-10-17 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE19807505A1 (de) 1998-02-21 1999-08-26 Roland Man Druckmasch Bogenrotationsdruckmaschine mit Druckeinheiten für den Mehrfarbendruck und wenigstens einer Beschichtungseinheit
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE69927790T2 (de) 1998-02-25 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
AU5325699A (en) * 1998-08-12 2000-03-06 Proteus Inc. Ribbed core dual wall structure
CN1122668C (zh) 1998-12-22 2003-10-01 诺瓦提斯公司 环氧噻酮衍生物，其制备方法及其药物组合物
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
US6605559B1 (en) * 1999-09-29 2003-08-12 Daihatsu Motor Co., Ltd. Dimethyl ether reforming catalyst
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
EP1353667A1 (en) * 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
EE05301B1 (et) 2001-01-25 2010-06-15 Bristol-Myers Squibb Company Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks
US9317043B2 (en) 2013-12-19 2016-04-19 Google Inc. Path based power generation control for an aerial vehicle

Also Published As

Publication number Publication date
AR034259A1 (es) 2004-02-18
CZ2003418A3 (cs) 2004-01-14
YU12103A (sh) 2006-08-17
IL153993A (en) 2009-07-20
UY26886A1 (es) 2002-03-22
HUP0300826A2 (hu) 2003-09-29
US6982276B2 (en) 2006-01-03
DE60129334D1 (en) 2007-08-23
RU2272039C2 (ru) 2006-03-20
BG66132B1 (bg) 2011-06-30
JP2004506638A (ja) 2004-03-04
US20020188014A1 (en) 2002-12-12
SI21100A (sl) 2003-06-30
NO328500B1 (no) 2010-03-01
UA75365C2 (en) 2006-04-17
CA2418109C (en) 2011-09-27
IS6714A (is) 2003-02-11
LT2003017A (en) 2004-03-25
EP1309597A2 (en) 2003-05-14
EE200300063A (et) 2004-12-15
RO123296B1 (ro) 2011-06-30
EE05273B1 (et) 2010-02-15
TWI320040B (en) 2010-02-01
ES2288518T3 (es) 2008-01-16
US6689802B2 (en) 2004-02-10
HK1052010A1 (en) 2003-08-29
SI21100B (sl) 2009-12-31
GEP20053495B (en) 2005-04-25
KR100810342B1 (ko) 2008-03-07
CN1269821C (zh) 2006-08-16
CN1468243A (zh) 2004-01-14
LT5138B (lt) 2004-06-25
EP1309597B1 (en) 2007-07-11
WO2002014323A3 (en) 2002-05-02
US7153879B2 (en) 2006-12-26
PT1309597E (pt) 2007-08-22
ZA200300522B (en) 2004-04-20
HUP0300826A3 (en) 2005-05-30
PL205628B1 (pl) 2010-05-31
SK1342003A3 (en) 2003-09-11
BG107467A (bg) 2003-09-30
SK287876B6 (sk) 2012-02-03
ATE366735T1 (de) 2007-08-15
NO20030707D0 (no) 2003-02-14
IL153993A0 (en) 2003-07-31
BR0113234A (pt) 2004-02-25
DE60129334T2 (de) 2008-04-03
CA2418109A1 (en) 2002-02-21
USRE39251E1 (en) 2006-08-29
MXPA03001431A (es) 2004-05-04
PL365610A1 (en) 2005-01-10
HRP20030190B1 (en) 2011-07-31
PE20020290A1 (es) 2002-04-03
WO2002014323A2 (en) 2002-02-21
JP5046467B2 (ja) 2012-10-10
AU8108201A (en) 2002-02-25
DK1309597T3 (da) 2007-10-22
IS2845B (is) 2013-08-15
HRP20030190A2 (en) 2003-04-30
NO20030707L (no) 2003-04-15
HU229314B1 (en) 2013-10-28
US20060063815A1 (en) 2006-03-23
KR20030022411A (ko) 2003-03-15
AU2001281082B2 (en) 2007-01-04
MY134129A (en) 2007-11-30
LV13032B (en) 2003-12-20
NZ523722A (en) 2005-04-29
US20040157897A1 (en) 2004-08-12
CZ305523B6 (cs) 2015-11-18

Similar Documents

Publication Publication Date Title
CY1107758T1 (el) Πολυμορφα ενος αναλογου εποθεινολης
CY1106890T1 (el) Παραγωγα της ακριδινης και η χρηση τους ως φαρμακων
PA8547701A1 (es) Nucleosidos 4 substituidos.
CY1108279T1 (el) 17α-ΑΛΚΥΛΟ-17β-ΟΞΥ-ΟΙΣΤΡΑΤΡΙΕΝΙΑ ΚΑΙ ΕΝΔΙΑΜΕΣΑ ΠΡΟΪΟΝΤΑ ΓΙΑ ΤΗΝ ΠΑΡΑΓΩΓΗ ΑΥΤΩΝ, Η ΧΡΗΣΗ ΤΩΝ 17α-ΑΛΚΥΛΟ-17β-ΟΞΥ-ΟΙΣΤΡΑΤΡΙΕΝΙΩΝ ΓΙΑ ΤΗΝ ΠΑΡΑΓΩΓΗ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΜΕΣΩΝ ΚΑΘΩΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΑ ΠΑΡΑΣΚΕΥΑΣΜΑΤΑ
SE9904505D0 (sv) Novel compounds
CY1105387T1 (el) Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
CY1108085T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπ-2-εν-1-ονης παρασκευη και χρησης αυτων
PA8591701A1 (es) Derivados de pirrolopirimidina
CY1111440T1 (el) 5-χλωρο-3-(4-μεθανοσουλφονυλφαινυλ)-6'-μεθυλ-[2,3']διπυριδινυλ σε καθαρη κρυσταλλικη μορφη και διαδικασια για συνθεση
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
BR0208338A (pt) Derivados de piridina
UY26839A1 (es) Productos de derivados de la 4 - fenil - piridina
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
CY1108770T1 (el) Νεα παραγωγα του ινδολιου και χρηση τους ως φαρμακων
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
CO4810375A1 (es) Derivados de 9-amino-3-ceto eritromicina
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
AR012504A1 (es) Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion.
FR2359830A1 (fr) 6-alcoyl-pyrimidines utilisables comme medicament, notamment contre la malaria
TR200402454T4 (tr) C-4 karbonat taksanlar.
CY1105275T1 (el) Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
CY1106964T1 (el) Φαρμακα που περιεχουν ν,ν’-διυποκατεστημενες ενωσεις πιπεραζινης και η χρησιμοποιηση τους
DK1000067T3 (da) Thiazolobenzoheterocycliske forbindelser, deres fremstilling og lægemidler indeholdende forbindelserne